Form 4: Ultragenyx Director Sanders Reports Acquisition and Disposal of Shares

Director Corazon Sanders reports acquiring and disposing of Ultragenyx Pharmaceutical Inc. shares, including restricted stock units and stock options.

Summary

• On June 18, 2024, Corazon Sanders, a director of Ultragenyx Pharmaceutical Inc., reported transactions involving the company's stock.
• Sanders acquired 5,345 shares of common stock through an award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
• These RSUs will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Sanders also disposed of 5,345 shares of common stock.
• Additionally, Sanders acquired 9,900 stock options with an exercise price of $37.42, which will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.
• Following these transactions, Sanders beneficially owns 12,593 shares of common stock and 9,900 stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The RSUs and stock options will vest on the earlier of the company's next Annual Meeting of Stockholders or June 18, 2025.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a company (such as directors or officers) trade in the company's securities. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The disclosure of insider transactions provides transparency to shareholders regarding the actions of company directors.

Key Dates